Inflammation and lipid-lowering treatment.
Leukocytes play a critical role in both the initial steps of atherogenesis and the late events of plaque instability and thrombosis. Leukocyte-endothelial cell adhesion molecules (CAMs) modulate the interaction between circulating leukocytes and the vessel wall. Levels of soluble CAMs are increased in patients with dyslipidemia or other risk factors, and levels can be reduced by lipid-modifying therapy. Novel markers of inflammation and atherosclerosis may be useful to identify high-risk individuals and to assess the efficacy of antiatherosclerotic therapy.
Ballantyne
C M
CM
Department of Medicine, Baylor College of Medicine, 6565 Fannin, MS A-601, Houston, Texas 77030, USA.
Abe
Y
Y
D015415:Biomarkers; D015815:Cell Adhesion Molecules / Q000502:physiology*; D006801:Humans; D006949:Hyperlipidemias / Q000503:physiopathology*; D015228:Hypertriglyceridemia / Q000503:physiopathology; D000960:Hypolipidemic Agents; D007249:Inflammation / Q000503:physiopathology*; D018799:Intercellular Adhesion Molecule-1 / Q000502:physiology; D012307:Risk Factors; D019010:Vascular Cell Adhesion Molecule-1 / Q000502:physiology
D015415:Biomarkers; D015815:Cell Adhesion Molecules; D000960:Hypolipidemic Agents; D019010:Vascular Cell Adhesion Molecule-1; D018799:Intercellular Adhesion Molecule-1